Thank you to those who at #PMWC17 came up to introduce themselves! https://t.co/lkWAQRCFg8
7:43pm January 25th 2017 via Hootsuite
Rittenhouse: erlotinib-treted pt shown; day 4 T790M shown. day 25 tissue genotyping shown T790M, day 31 osimertinib responder #PMWC17
2:11pm January 25th 2017 via Hootsuite
Rittenhouse: Safety, cost, logistics, TAT: all problematic, so plasma testing attractive. #PMWC17
2:10pm January 25th 2017 via Hootsuite
Rittenhouse: Targeting EGFR in lung ca T790M point mutation; 3rd gen TKI (osimertinib) now req a re-biopsy. Plasma testing allowed. #PMWC17
2:09pm January 25th 2017 via Hootsuite
Lauren Rittenhouse (Brigham and Women's Hosp Harvard): Complementarity of dPCR and NGS #PMWC17
2:08pm January 25th 2017 via Hootsuite
.@helixcode Hi - in all the talks I attended, CNV from exomes not mentioned at all here at #PMWC17
2:08pm January 25th 2017 via Hootsuite in reply to helixcode
.@Genomes2People @RobertCGreen Thank you for the kind word! Always, always enjoy Dr. Green's presentations; IIRC only heard him once before.
2:06pm January 25th 2017 via Hootsuite in reply to Genomes2People
.@jgreid Alas I missed the BGI talk - due to travel delay. Would reach out to Rado, or BGI-Americas. On second Q not sure, sorry.
2:05pm January 25th 2017 via Hootsuite in reply to jgreid
.@OmicsOmicsBlog Hi Keith - IIRC it was just the platform ("Roche Sequel") rather than a Roche assay.
9:13am January 25th 2017 via Hootsuite in reply to OmicsOmicsBlog
.@LincolnNadauld I do agree - the overall costs of WGS (incl analysis) is high, and a classic 'don't throw the baby w/the bathwater' #PMWC17
9:11am January 25th 2017 via Hootsuite in reply to LincolnNadauld
.@CrowdedHead You are most welcome! Quite a privilege to be here - thanks to @SeraCare
9:10am January 25th 2017 via Hootsuite in reply to CrowdedHead
.@atulbutte Key to a long life: be a non-purple dot. :)
9:08am January 25th 2017 via Hootsuite in reply to atulbutte
Garlick: Working with NIST and EDRN for ctDNA with reference materials #PMWC17
4:39pm January 24th 2017 via Hootsuite
Garlick: SeraCare is bringing products to FDA; de-novo application of 37 ver's at 10% VAF #PMWC17
4:37pm January 24th 2017 via Hootsuite
Garlick: Millions of NIPT samples/year yet no PT program in place. Tapestry network - 'Oncologists concerned CDx about lab results' #PMWC17
4:35pm January 24th 2017 via Hootsuite
Garlick: 2/6 labs report incorrect cardiomyopathy results (Vrijenhoek in EJHG) #PMWC17
4:34pm January 24th 2017 via Hootsuite
Russell Garlick (CSO SeraCare) Achieving Accurate NGS Test Results #PMWC17 NIPS error rate is 3.8%
4:33pm January 24th 2017 via Hootsuite
Q: Scene in China? Beresford: Feel that it'll become std of care sooner in China than here. #PMWC17
3:18pm January 24th 2017 via Hootsuite
Beresford: Shortening time from Dx to Rx '16 ref https://t.co/Pge68IaxIf #PMWC17
3:15pm January 24th 2017 via Hootsuite
Beresford: "actionable results in 72h for pts with NSCLC" - shortening time from Dx to Rx for NSCLC. Usually 3-6w for tissue testing #PMWC17
3:13pm January 24th 2017 via Hootsuite
Beresford: genestrat test now has actionable muts (EGFR, ALK, ROS, RET), also T790M result; reflex to verstrat for Pt-Rx or TKI #PMWC17
3:12pm January 24th 2017 via Hootsuite
Beresford: Prognostic, based upon 8 parameters. Describes advanced-NSCLC for their VeriStat, covered by Medicare, 220M pt coverage #PMWC17
3:11pm January 24th 2017 via Hootsuite
Beresford: Estimated 150K publications for biomarkers. They have a MALDI-ToF MS test called VeriStrat, with spectra #PMWC17
3:07pm January 24th 2017 via Hootsuite
Paul Beresford (Biodesix) Discovering, developing, validating and commercializing liquid biopsy tests in oncology #PMWC17
3:06pm January 24th 2017 via Hootsuite
Otto: Critical to look beyond ctDNA - CTCs, tissues, proteins, RNA. #PMWC17
3:03pm January 24th 2017 via Hootsuite
Otto: Need to demonstrate contam. control, detection. Precision for intra- and inter-run. Also concordance w/orthogonal validation #PMWC17
3:02pm January 24th 2017 via Hootsuite
Otto: Claim 50% conversion efficiency for >5000x sequencing. Analytic validation - use mix of cell lines, synthetic spike-ins #PMWC17
3:01pm January 24th 2017 via Hootsuite
Otto: They've built kits to maximize stability. Also: how to interpret negative results? 2w stability in their kits. #PMWC17
3:00pm January 24th 2017 via Hootsuite
Otto: Clinical challenge: no path review, thus need for low AF measurement. Need SNV, indel, CNA, fusions. Limited smpl stablity #PMWC17
2:57pm January 24th 2017 via Hootsuite
Otto: Yield, dynamic range is highly variable. ctDNA is indirect interrogation. Potential insight into 'systemic' disease (resist) #PMWC17
2:55pm January 24th 2017 via Hootsuite
Geoff Otto (Foundation Medicine) Development and analytic validation of a ctDNA genomic profiling assay #PMWC17
2:53pm January 24th 2017 via Hootsuite
Pralahad: Developed 200 documents for CAP, down to single-cell level. Collab w/Genomic Health, also participating in Moonshot #PMWC17
2:52pm January 24th 2017 via Hootsuite
Pralahad: Looking at AR-V7, published JAMA '16 https://t.co/uaMeBs5vf2 want to optimize process from phlebotomy to result #PMWC17
2:50pm January 24th 2017 via Hootsuite
Pralahad: Go back with dyes, Ab-conj, to interogate cells on the 2D slide surface. First: mCRPC (metastatic chemo-resist Prostate C) #PMWC17
2:49pm January 24th 2017 via Hootsuite
Outgoing FDA Commissioner, Pharma, Investors Discuss Regulation at #PMWC17 | GenomeWeb ($) https://t.co/LO4FHXCQA2
2:48pm January 24th 2017 via Hootsuite
Pralahad: Makes the case for CTCs monitoring complex, metastatic disease. Look at all nucleated cells, find shape-based outliers #PMWC17
2:46pm January 24th 2017 via Hootsuite
Murali Pralahad (EPIC) Actionable, accurate and accessible liquid biopsy #PMWC17
2:43pm January 24th 2017 via Hootsuite
Pla: And spec shown per-sample, not per-base. They require 2x 10mL blood, spec. >99% on a per-sample basis #PMWC17
2:42pm January 24th 2017 via Hootsuite
Pla: Lack of standardization how data is reported, can mislead. No single measure - report sens for SNVs, indels, Fusions, CNV gain #PMWC17
2:41pm January 24th 2017 via Hootsuite
Pla: Analytical performance - base specificity, incorrect calls/sample based on 100kb panels has 100 incorrect calls at 99.9% #PMWC17
2:40pm January 24th 2017 via Hootsuite
Frederick Pla (Genomic Health): Timelines for adoption of ctDNA to $26B market depending on indication. Oncotype SEQ Liquid Select #PMWC17
2:38pm January 24th 2017 via Hootsuite
Butte: Next big data to share? Wuest: Individual connected devices. Filling in lots of gaps that are needed (i.e. mood, depression) #PMWC17
2:29pm January 24th 2017 via Hootsuite
Wuest: Perhaps sharing of clinical data anonymously. #PMWC17
2:24pm January 24th 2017 via Hootsuite
Q: Value of neg. results? Butte: Still an environment of distrust; sharing starts with journal editors, to funding agencies, to law #PMWC17
2:23pm January 24th 2017 via Hootsuite
Wuest: Huntington's, diabetes (Pfizer). New biology (multiple myeloma, Cardio), interventions (MS w/Novartis, diabetes w/Sanofi) #PMWC17
2:06pm January 24th 2017 via Hootsuite
Wuest: Combined with optimization, using ensemble of networks using Monte Carlo simulation. Used for biomarker discovery #PMWC17
2:05pm January 24th 2017 via Hootsuite
Wuest: GNS has a Reverse Engineering Forward Simulation. Bayesian stats. Enumerating trillions of network fragments, scored as dist. #PMWC17
2:03pm January 24th 2017 via Hootsuite
Diane Wuest (GNS Healthcare) Unlocking precise knowledge w/in complex data via causal machine learning #PMWC17
1:58pm January 24th 2017 via Hootsuite
Atul Butte’s future map of death and dying, over time. #PMWC17 The purple end-point is sepsis. https://t.co/auofaYgFHv
1:54pm January 24th 2017 via Hootsuite
Butte: Google Maps still can't show all the cars. 2019 - want to show a real-time map of patient. Amazing animation shown. #PMWC17
1:52pm January 24th 2017 via Hootsuite
